Free tool
FAERS Monitor: Thyquidity
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 214047 or its brand name (Thyquidity, Levothyroxine Sodium). Reports on generic versions are filed under their own applications.
Reports
101,627
Serious
70,399
69% of reports
Hospitalization
39,132
Death reported
8,379
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- fatigue8,319
- nausea7,284
- diarrhoea6,612
- headache6,429
- dyspnoea6,344
- drug ineffective5,447
- pain5,351
- dizziness5,095
- vomiting4,553
- asthenia4,373
- off label use4,143
- fall4,135
- malaise4,100
- arthralgia3,998
- pruritus3,494
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 2,043 |
| 2005 | 2,018 |
| 2006 | 2,180 |
| 2007 | 2,759 |
| 2008 | 4,015 |
| 2009 | 3,823 |
| 2010 | 4,305 |
| 2011 | 6,146 |
| 2012 | 6,819 |
| 2013 | 1,398 |
| 2014 | 1,713 |
| 2015 | 2,374 |
| 2016 | 3,138 |
| 2017 | 3,607 |
| 2018 | 4,138 |
| 2019 | 4,005 |
| 2020 | 5,441 |
| 2021 | 5,809 |
| 2022 | 7,395 |
| 2023 | 6,974 |
| 2024 | 7,352 |
| 2025 | 8,276 |
| 2026 | 5,898 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 20,952,532 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| fallSignal | 4,135 | 2.6 | 2.5 | 4,052 |
| astheniaSignal | 4,373 | 2.4 | 2.4 | 3,678 |
| dyspnoeaSignal | 6,344 | 2.3 | 2.3 | 4,915 |
| fatigueSignal | 8,319 | 2.2 | 2.2 | 5,759 |
| headacheSignal | 6,429 | 2.1 | 2.1 | 3,950 |
| diarrhoeaSignal | 6,612 | 2.1 | 2.1 | 4,054 |
| dizzinessSignal | 5,095 | 2.1 | 2.1 | 3,078 |
| vomitingSignal | 4,553 | 2.0 | 2.0 | 2,353 |
| arthralgia | 3,998 | 2.0 | 1.9 | 2,018 |
| malaise | 4,100 | 1.9 | 1.9 | 1,899 |
| nausea | 7,284 | 1.9 | 1.9 | 3,267 |
| pruritus | 3,494 | 1.9 | 1.8 | 1,476 |
| pain | 5,351 | 1.8 | 1.8 | 1,979 |
| off label use | 4,143 | 1.0 | 1.0 | 2 |
| drug ineffective | 5,447 | 0.9 | 0.8 | 143 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.